Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis

2 Nov 2022

Abstract excerpt

Prostate cancer (PCa) is a type of potentially fatal malignant tumor. Immunotherapy has shown a lot of potential for various types of solid tumors, but the benefits have been less impressive in PCa. Enhancer of zeste homolog 2 (EZH2) is one of the three core subunits of the polycomb repressive complex 2 that has histone methyltransferase activity, and the immune effects of EZH2 in PCa are still unclear. The...

Source

Identifiers

PMID: 36358967
DOI: 10.3390/biom12111617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico AnalysisPMID 36358967Read ↗

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersSemantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate CancerSemantic proximity Read ↗

Bioinformatic determination of the expression and clinical value of the histone lysine demethylase family in prostate cancerSemantic proximity Read ↗

Coordinating single‐cell and bulk RNA ‐seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patientsSemantic proximity Read ↗

Predicting Prostate Adenocarcinoma Patients’ Survival and Immune Signature: A Novel Risk Model Based on Telomere-Related GenesSemantic proximity Read ↗

Identification of Prostate Cancer Subtypes Based on Immune Signature Scores in Bulk and Single Cell TranscriptomesSemantic proximity Read ↗

The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer TreatmentSemantic proximity Read ↗

Development of a Novel Immune-Related Prognostic Signature for Prostate CancerSemantic proximity Read ↗

Immune-Related Gene-Based Novel Subtypes to Establish a Model Predicting the Risk of Prostate CancerSemantic proximity Read ↗

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltratesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.